Navigation Links
United States Market for Psoriatic Arthritis Pharmacotherapy
Date:7/10/2012

NEW YORK, July 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

United States Market for Psoriatic Arthritis Pharmacotherapy

http://www.reportlinker.com/p0925230/United-States-Market-for-Psoriatic-Arthritis-Pharmacotherapy.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This research service covers the United States psoriatic arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed and used as well as the background standard of care. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics and novel oral disease-modifying antirheumatic drugs (DMARDs).

Executive Summary•The market for psoriatic arthritis (PsA) pharmacotherapeutics is currently comprised of a single class: tumor necrosis factor (TNF) inhibitors. Availability of alternative therapies for anti-TNF refractory patients represents a significant unmet need.•Revenue generated from sales of TNF inhibitors for PsA in the United States was approximately $xxx.x million in 2011 and dominated by Amgen. Revenue for the PsA therapeutic area is expected to increase to approximately $x,xxx.x million in 2017, aided by the addition of several new therapies to the market.•Novel therapies aimed at alternative targets such as interleukin 12/23 (IL-12/23), interleukin-17 (IL-17), interleukin-6 (IL-6), phosphodiesterase type 4 (PDE4) and janus kinase (JAK) are in active development, with a PDE4 inhibitor and an anti-IL-12/23 closest to approval for PsA.•Development of therapies for this complex disease and market penetration is hindered by several factors including a perception of PsA as a milder disease compared to rheumatoid arthritis (RA), and incompletely understood pathogenesis.•Although some therapies such as TNF inhibitors that are effective for the treatment of RA are also effective for PsA, this is not always the case due to differences between the two diseases.•Accumulating evidence supporting the importance of prompt initiation of effective disease modifying therapy for better long-term outcomes for patients with PsA is driving development of novel therapies aimed at improving symptoms and slowing disease progression.•Estimates of the prevalence of PsA vary widely, but it is generally considered to occur in approximately xx to xx percent of psoriasis sufferers, or approximately xxx,xxx to x.x million men and women in the United States.•Diagnostic difficulties are thought to result in unawareness of the condition by many patients and significant under-treatment.

TABLE OF CONTENTS

Executive Summary 4

Market Overview 10

Psoriatic Arthritis Pharmacotherapeutics Market -

External Challenges: Drivers and Restraints 20

Forecast and Trends 30

Demand Analysis 41

Market Share and Competitive Analysis 44

TNF Inhibitor Segment Breakdown 54

Non-TNF Biologics Segment Breakdown 65

Novel Oral DMARDs Segment Breakdown 73

The Last Word 81

Appendix 86

To order this report: Pathology Industry: United States Market for Psoriatic Arthritis Pharmacotherapy 

More  Market Research Report Check our  Industry Analysis and Insights

Nicolas Bombourg Reportlinker Email: nicolasbombourg@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. United States Surgical Equipment Market Outlook to 2018- Electrosurgical Devices, Hand Instruments and Surgical Sutures
2. United Kingdom ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
3. Zimmer Introduces First Porous Metal Interbody Implant for Lumbar Spine in the United States
4. United States ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
5. United Spinal To "Roll on Capitol Hill:" Voices Aim to Impact Federal Health Care Policy
6. Eleven Integrated Health Systems Form Largest Private-Sector Diabetes Registry in United States
7. Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. K-V Pharmaceutical Company States That Its Policy is Not to Comment on Unusual Market Activity
10. Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
11. Analysis of the North American Radiology Image and Information Management Systems Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):